| Ident. | Authors (with country if any) | Title |
|---|
| 000587 (2021) |
Susan Gould [Royaume-Uni] ; Susan L. Norris [États-Unis] | Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19. |
| 000591 (2021) |
Jonne J. Sikkens [Pays-Bas] ; Didier Collard [Pays-Bas] ; Edgar J G. Peters [Pays-Bas] | Comparison of hospital treatment strategy or of treatment actually received in COVID-19?: Commenting on: Lammers AJJ, Brohet RM, Theunissen REP, Koster C, Rood R, Verhagen DWM, et al. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. Int J Infect Dis. 2020 September. |
| 000628 (2021) |
Malin-Theres Seffer [Allemagne] ; Jens Martens-Lobenhoffer [Allemagne] ; Julius J. Schmidt [Allemagne] ; Gabriele Eden [Allemagne] ; Stefanie M. Bode-Böger [Allemagne] ; Jan T. Kielstein [Allemagne] | Clearance of chloroquine and hydroxychloroquine by the Seraph® 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients. |
| 000631 (2021) |
Mohammad Bahadoram [Iran] ; Bijan Keikhaei [Iran] ; Ali Saeedi-Boroujeni [Iran] ; Mohammad-Reza Mahmoudian-Sani [Iran] | Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19? |
| 000633 (2021) |
Bhagteshwar Singh [Royaume-Uni, Inde] ; Hannah Ryan [Royaume-Uni] ; Tamara Kredo [Afrique du Sud] ; Marty Chaplin [Royaume-Uni] ; Tom Fletcher [Royaume-Uni] | Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. |
| 000634 (2021) |
Pauloc Greg Rio [Brésil] ; Regiane S. Da Cunha [Brésil] ; Gilson Biagini [Brésil] ; Bruna Bosquetti [Brésil] ; Júlia Budag [Brésil] ; Alberto Ortiz [Espagne] ; Maria Dolores Sánchez-Ni O [Espagne] ; Fellype C. Barreto [Brésil] ; Andréa E M. Stinghen [Brésil] | Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. |
| 000635 (2021) |
Edward J. Calabrese [États-Unis] ; Jaap C. Hanekamp [Pays-Bas] ; Yannic N. Hanekamp [Pays-Bas] ; Rachna Kapoor [États-Unis] ; Gaurav Dhawan [États-Unis] ; Evgenios Agathokleous [République populaire de Chine] | Chloroquine commonly induces hormetic dose responses. |
| 000636 (2021) |
Bruno Mégarbane [France] | Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. |
| 000639 (2021) |
Amin Gasmi [France] ; Massimiliano Peana [Italie] ; Sadaf Noor [Pakistan] ; Roman Lysiuk [Ukraine] ; Alain Menzel [Luxembourg (pays)] ; Asma Gasmi Benahmed [France] ; Geir Bj Rklund [Norvège] | Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. |
| 000640 (2021) |
Ernesto Carafoli [Italie] | Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection. |
| 000641 (2021) |
Rashmi R. Shah [Royaume-Uni] | Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. |
| 000642 (2021) |
Dominik Majewski [Pologne] ; Katarzyna Anna Majewska [Pologne] ; Monika Naskr Cka [Pologne] ; Bogna Grygiel-G Rniak [Pologne] | Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective. |
| 000645 (2021) |
Riadh Badraoui [Arabie saoudite, Tunisie] ; Mohd Adnan [Arabie saoudite] ; Fevzi Bardakci [Arabie saoudite, Turquie] ; Mousa M. Alreshidi [Arabie saoudite] | Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism. |
| 000652 (2021) |
Jia Fu [République populaire de Chine] ; Qianqian Jia [République populaire de Chine] ; Huaxin Zhou [République populaire de Chine] ; Liyang Zhang [République populaire de Chine] ; Saisai Wang [République populaire de Chine] ; Peida Liang [République populaire de Chine] ; Yanni Lv [République populaire de Chine] ; Shengli Han [République populaire de Chine] | Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. |
| 000653 (2021) |
Adam Goldman [Israël] ; David Bomze [Israël, Suisse] ; Rachel Dankner [Israël] ; Hanoch Hod [Israël] ; Tomer Meirson [Israël] ; Ben Boursi [Israël, États-Unis] ; Elad Maor [Israël] | Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. |
| 000655 (2021) |
Pierre Jordaan [Suisse] ; Bérengère Dumotier [Suisse] ; Martin Traebert [Suisse] ; Paul E. Miller [États-Unis] ; Andre Ghetti [États-Unis] ; Laszlo Urban [États-Unis] ; Najah Abi-Gerges [États-Unis] | Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes. |
| 000663 (2021) |
Miroslaw Kiedrowski [Pologne] ; Przemyslaw Kapala [Pologne] ; Marlena Kiedrowska [Pologne] ; Anna Skoczynska [Pologne] ; Aleksandra Czerw [Pologne] ; Andrzej Deptała [Pologne] | Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. |
| 000690 (2021) |
Carlotta Sciaccaluga [Oman] ; Matteo Cameli [Italie] ; Daniele Menci [Italie] ; Giulia Elena Mandoli [Italie] ; Nicol Sisti [Italie] ; Paolo Cameli [Italie] ; Federico Franchi [Italie] ; Sergio Mondillo [Italie] ; Serafina Valente [Italie] | COVID-19 and the burning issue of drug interaction: never forget the ECG. |
| 000691 (2021) |
Kieran Murray [Irlande (pays)] ; Sean Quinn [Irlande (pays)] ; Matthew Turk [Irlande (pays)] ; Anna O'Rourke [Irlande (pays)] ; Eamonn Molloy [Irlande (pays)] ; Lorraine O'Neill [Irlande (pays)] ; Ann Barbara Mongey [Irlande (pays)] ; Ursula Fearon [Irlande (pays)] ; Douglas J. Veale [Irlande (pays)] | COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population. |
| 000699 (2021) |
Mark Szendrey [Canada] ; Jun Guo [Canada] ; Wentao Li [Canada] ; Tonghua Yang [Canada] ; Shetuan Zhang [Canada] | COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. |
| 000729 (2021) |
Ambedkar Kumar Yadav [République populaire de Chine] ; Siwan Wen [République populaire de Chine] ; Xianghuai Xu [République populaire de Chine] ; Li Yu [République populaire de Chine] | Antiviral treatment in COVID-19: which is the most promising?-a narrative review. |
